Search
Search Results
##search.searchResults.foundPlural##
-
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1650PDF: 644HTML: 2429 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
966PDF: 530HTML: 720 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
1796PDF: 799HTML: 10229Figures 1,2,3: 172 -
-
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2461PDF: 918HTML: 519 -
THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.
10549PDF: 6330HTML: 21779 -
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa
6794PDF: 3638HTML: 750 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3673PDF: 1233HTML: 3880Untitled: 207Untitled: 257 -
Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia
2907PDF: 682HTML: 1932figure 1: 167figure 2: 176 -
TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY
3542PDF: 1063HTML: 873 -
TIMING FOR STEP-DOWN THERAPY OF CANDIDEMIA IN NON-NEUTROPENIC PATIENTS: AN INTERNATIONAL MULTI-CENTER STUDY Stepdown Therapy of Candidemia
2041PDF: 636HTML: 260 -
-
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1321PDF: 814HTML: 126 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
2768PDF: 1011HTML: 360Preferred Reviewers: 203 -
EARLY PREDICTIVE VALUE OF PERIPHERAL INFLAMMATORY INDEX COMBINED WITH HIGH-SENSITIVITY TROPONIN T FOR SEPSIS-INDUCED CARDIOMYOPATHY Inflammatory and Troponon T in cardiomyopaty from Sepsis
161PDF: 172HTML: 12 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2159PDF: 1467HTML: 262 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
1972PDF: 1118HTML: 614 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
981PDF: 1158Suppl. Files: 144HTML: 66 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2160PDF: 1998HTML: 169 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2572PDF: 797HTML: 5207 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2250PDF: 1812HTML: 140 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3530PDF: 2394HTML: 1454 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3364PDF: 1288HTML: 1861Fig.1: 198Fig. 2: 203 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2207PDF: 957HTML: 1889 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3224PDF: 1329HTML: 4128 -
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
2778PDF: 1112HTML: 11215 -
A STUDY ON THE EXPRESSION OF BCR-ABL TRANSCRIPT IN MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) CASES USING THE REVERSE TRANSCRIPTASE POLYMERASE REACTION ASSAY (RT-PCR) AND ITS CORRELATION WITH HEMATOLOGICAL REMISSION STATUS POST INITIAL INDUCTION THERAPY
1339PDF: 811HTML: 5032INSTITUTE PUBLICATION COMMITTEE APPROVAL: 159 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3248PDF: 1525HTML: 415 -
DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE
3660PDF: 1279HTML: 725Figure 2: 449Figure 1: 3114 -
FAMILIAL MEDITERRANEAN FEVER AND HYPERCOAGULABILITY
1200PDF: 710HTML: 1230







